Under the pharmacological consensus (Heinrich et al., 2020), we composed this study and assumed that DHD might be involved in suppressing RANKL-mediated osteoclasts formation and its downstream molecular mechanism. The gene discussed is TNFSF11; the disease is Doyne honeycomb retinal dystrophy.